Dr. Reddy's Laboratories Reports Quality Issues with Semaglutide Batches, Announcing Supply Delays
Dr. Reddy's Laboratories Limited has reported that certain batches of semaglutide have been found to be out of specification due to an issue related to the active pharmaceutical ingredient (API) used in the product. The company is actively investigating the root cause of this matter and implementing necessary measures to uphold product quality standards.The company stated that, while investigations are underway, commercial supplies of the semaglutide product will be delayed until the underlying issue has been fully resolved. Dr. Reddy's Laboratories reassured stakeholders that there is no impact on patient safety regarding the affected batches or any existing global regulatory filings for the product. The company remains dedicated to ensuring reliable global availability of this essential metabolic therapy.
The management of Dr. Reddy's Laboratories hosted a conference call to discuss the issue and address participant questions, reinforcing its commitment to the quality and consistent supply of semaglutide.
DRREDDY Stock Price Movement
As of 9:24 AM, shares of Dr. Reddy's Laboratories Limited are slipping in live trading, falling by 2.20% to trade at ₹1319.3 as the market unfolds. The stock experienced significant intraday volatility, navigating a range between the low of ₹1315.1 and the high of ₹1341.9, while recording a volume of 576,778 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.